We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Goldshield Grp | LSE:GSD | London | Ordinary Share | GB0002893823 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 486.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:4830F Goldshield Group PLC 23 December 2002 23 December 2002 Goldshield Group plc ("Goldshield" or "the Company") Claim from The Secretary of State for Health Goldshield Group plc announces that it has received a claim for damages from The Secretary of State for Health and certain other claimants arising from the sale and supply of the anticoagulant drug Warfarin between 1996 and 2000. Goldshield intends to defend the claim vigorously. The Secretary of State for Health together with The Prescription Pricing Authority and twenty-eight Strategic Health Authorities ("the Claimants") have issued a claim in the High Court in London against Norton Healthcare Limited, Norton Pharmaceuticals Limited, Regent-GM Laboratories Limited, Goldshield Group plc, Goldshield Pharmaceuticals Limited and Forley Generics Limited seeking damages of #28,584,748. Goldshield Pharmaceuticals Limited and Forley Generics Limited are wholly owned subsidiaries of Goldshield. Norton Healthcare Limited, Norton Pharmaceuticals Limited and Regent-GM Laboratories are entirely unconnected with the Goldshield Group. The Claimants allege that arrangements were conducted in respect of the sale and supply of Warfarin in the United Kingdom between 1996 and 2000 in breach of competition laws entitling them to claim damages from the Goldshield Group and the other parties named in their claim. The Goldshield does not believe that it has acted in an anti-competitive or improper way and intends to defend the legal proceedings vigorously. Goldshield sells prescription pharmaceuticals and other non-prescription medicines through its Pharmaceutical Division and a range of vitamins, minerals, supplements and a wide range of other healthcare products through its Healthcare Division. During the period 1st January 1996 and 31st December 2000 Goldshield's Pharmaceutical Division made total sales to the National Health Service of approximately #6.9 million of Warfarin-based pharmaceuticals representing 3.7% of the Goldshield Group's total turnover of approximately #185 million during this period (based on the Company's internal financial records). On 10 April 2002, the Company announced that it was the subject of a separate investigation by the Serious Fraud Office ("SFO") in respect of a suspected conspiracy to defraud the National Health Service involving the prices charged by suppliers of penicillin-based antibiotics and Warfarin during the period from 1st January 1996 to 31st December 2000. Goldshield has never sold any penicillin-based antibiotics. Goldshield understood that five other companies were also under investigation by the SFO which has still to announce the outcome of its investigation. The Company maintains that it has conducted its business affairs in a lawful and proper manner. The Company and its Advisors are constrained by the legal proceedings from making any further comment. - ENDS - This information is provided by RNS The company news service from the London Stock Exchange END MSCFGMZZNMRGZZM
1 Year Goldshield Chart |
1 Month Goldshield Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions